Unlocking the Secrets of 1,5-AG: How a New Model Could Revolutionize Diabetes Monitoring During Pregnancy
"A computational approach sheds light on 1,5-AG dynamics, offering new insights for managing diabetes in pregnancy and potentially reducing risks for both mother and child."
For women with diabetes, maintaining healthy blood sugar levels is essential for a safe pregnancy and a healthy baby. Traditional biomarkers like HbA1c and daily glucose monitoring are commonly used, but they have limitations in capturing short-term glycemic fluctuations, especially during the critical gestational period. This is where 1,5-anhydroglucitol (1,5-AG) comes into play as a valuable, yet underutilized, biomarker.
1,5-AG is an intermediate biomarker that reflects glycemic control over a shorter period than HbA1c. It's also linked to increased diabetes risk and eclampsia during pregnancy. Despite its potential, physiological changes unique to pregnancy – like increased kidney filtration and plasma volume – can skew 1,5-AG levels, making interpretation tricky. A new computational model aims to clarify these dynamics, potentially revolutionizing how we monitor and manage diabetes in pregnancy.
Researchers have developed an innovative in-silico model of gestational 1,5-AG by integrating existing physiological data with a two-compartment mathematical model. This model builds on previous work to quantitatively assess the impact of renal and hemodynamic factors on 1,5-AG measurements during both normal and diabetic pregnancies. The findings offer a more precise understanding of 1,5-AG, enhancing its utility in clinical settings.
Reference Ranges and Pregnancy
Welter et al. (2018) determined reference intervals for serum 1,5-anhydroglucitol (1,5-AG) across age groups, including pregnant women. A companion data article compares 1,5-AG measurements across different conditions and methodologies. A 2024 review describes 1,5-AG as a glucose-like, non-metabolizable monosaccharide with the formula C6H12O5 and molecular mass 164.2. These sources establish relevant background, but the supplied material does not provide pregnancy-specific statistics or impact estimates.
Decoding 1,5-AG: What This Model Reveals About Pregnancy and Diabetes
The computational model confirms that a simple two-compartment model accurately reflects 1,5-AG kinetics during the first two trimesters of pregnancy for both normal and diabetic women. By adjusting parameters like reabsorption fraction, the model accounts for time-dependent changes, effectively capturing 1,5-AG dynamics.
- Confirms the involvement of renal and hemodynamic mechanisms: The model supports the idea that kidney function and blood flow significantly influence 1,5-AG levels during pregnancy.
- Clarifies expected 1,5-AG trends: By quantifying these influences, the model helps clinicians better understand what 1,5-AG levels mean in pregnant women.
- Highlights the need for further research: The model points to biological changes in the third trimester that warrant further investigation.
Emerging Pregnancy Research
A computational model study frames 1,5-AG as a potential complement to HbA1c, noting that mean HbA1c is a long-term measure and may not fully capture postprandial glycemic excursions. A prospective study in women with gestational diabetes assessed 1,5-AG and 1,5-AG/HOMA-IR and 1,5-AG/BMI trajectories during pregnancy and up to one year postpartum, and whether these measures predict postpartum glucose intolerance. A pilot study examined changes in 1,5-AG during gestation and postpartum and associations with other measures of glycemia. Separately, a report on type 2 diabetes describes 1,5-AG as indicating glycemic control over 1–2 weeks and as useful for monitoring postprandial hyperglycemia, while noting that its long-term predictive value is not fully established.
Limits and Measurement Challenges
A computational model reports that 1,5-AG dynamics in nondiabetic and diabetic pregnancy can be simulated with a two-compartment model with little adjustment before 25 weeks; after week 25, making the reabsorption fraction a function of gestational time improved model fit while retaining physiological parameters. A review notes concern that the lower renal glucose threshold in normal pregnancy may alter renal excretion of 1,5-AG and limit its ability to reflect glycemic changes. In type 2 diabetes, the association between 1,5-AG and traditional glycemic markers was attenuated among people with mGFR below 30 mL/min/1.73 m2. Another review notes there is no consensus on the best pregnancy glucose-monitoring method and that changes in insulin, lifestyle, appetite, insulin sensitivity, and red-cell turnover complicate interpretation of standard laboratory measures such as HbA1c.
Pregnancy Trends and Predictive Signals
A study of normal pregnancy reported that serum 1,5-AG decreased steadily from 9 weeks of gestation, reaching its lowest value in the third trimester: 10.2 ± 4.6 mg/L. In a separate study of type 2 diabetes and chronic kidney disease stages I–III, 1,5-AG concentrations averaged 27.2% lower in patients with glomerular hyperfiltration (eGFR above 120 mL/min) than in those with moderate renal impairment (eGFR 30–59 mL/min; P = 0.016). Among pregnancies complicated by type 1 diabetes, third-trimester 1,5-AG was the strongest predictor of macrosomia in the cited study, with an ROC AUC of 0.81 (95% CI 0.70–0.89). These findings address different populations and outcomes, so they do not establish a single direct comparison between 1,5-AG and other markers.
The Future of Diabetes Monitoring in Pregnancy
This computational model offers a significant step forward in understanding 1,5-AG dynamics during pregnancy. By confirming the role of renal and hemodynamic mechanisms and highlighting the unique changes of the third trimester, it paves the way for more effective use of this valuable biomarker. Further research is needed to fully elucidate the biological changes affecting 1,5-AG reabsorption and to refine the model for different diabetes subtypes. Ultimately, this knowledge can translate to improved clinical interpretation of 1,5-AG levels, leading to better management of diabetes in pregnancy and reduced risks for both mothers and their children.
Short-Term Glycemic Signal
A 2025 report describes serum 1,5-AG as an indicator of glycemic control over 1–2 weeks and as particularly useful for monitoring postprandial hyperglycemia. The source also cautions that its predictive value for long-term outcomes in type 2 diabetes has not been fully established. This supports treating 1,5-AG as a short-term signal rather than assuming it alone forecasts longer-term outcomes.
Building the Evidence Base
A 2024 review focuses on 1,5-AG’s biological characteristics, detection methods, and clinical applications, with the stated aim of supporting understanding and future applicable research. A separate review published May 1, 2026, summarizes its characteristics and clinical application in diabetes complications and aims to inform rational clinical use and future research. Together, the sources point to continued work on measurement and clinical application, but the supplied material does not specify validated future pregnancy-monitoring recommendations.
A Real-World Mortality Study
A real-world cohort study by Ni J, Chen L, Su H, and colleagues examined low serum 1,5-AG in relation to all-cause and cardiovascular mortality risk in people with type 2 diabetes. The supplied source material identifies the study’s question and citation but provides no results, cohort size, or effect estimates. It therefore cannot establish from this information how large any association was or how it should affect individual care.